Reply to the Editor  by Thistlethwaite, Patricia A. & Harrell, James
Our current strategy is to ‘‘perfuse
and watch’’ with the aid of real-time
monitoring and diagnostic imaging.
As Rescigno and colleagues mentioned,
near-infrared spectroscopy (NIRS) is
useful for detecting newly developed
cerebral malperfusion. Although they
recognized an undesirable situation by
inflow pressure and NIRS data, the for-
mer may not be apparent if the intima
breaks at the suture line and pressure el-
evation is not apparent. Decreased oxy-
gen saturation is likely to be a reliable
indicator of an occurrence of something
undesirable, whatever the cause.
Once malperfusion is detected, it is
necessary to develop an appropriate
strategy for restoring cerebral perfusion
based on the cause of malperfusion.
In this regard, visualization of the
‘‘Y-junction’’ with transesophageal
echocardiography can be helpful for
correctly pursuing the strategy, because
it provides real-time information on
morphology and perfusion.
However, the decision can be incor-
rect, as in our case. Thus, the decision
needs to be immediately assessed to
avoid further delay in restoring ade-
quate perfusion. This can be achieved
by NIRS. If oxygen saturation remains
low, other possible scenarios should be
considered.
We believe that a sequence of ‘‘de-
tection, decision, assessment’’ is impor-
tant in the operating room, especially in
cases of acute aortic dissection. To min-
imize ‘‘unfortunate events of unknown
cause,’’ it is necessary to fully use the
modalities available for obtaining real-
time information. This will be another
important task for cardiovascular sur-
geons, as well as surgical skill.
Kazumasa Orihashi, MD
Taijiro Sueda, MD
Kenji Okada, MD
Shinya Takahashi, MD
Hiroshima University Hospital
Hiroshima, Japan
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ENDOSCOPIC TREATMENT OF
AIRWAY STENOSIS AFTER
LUNG TRANSPLANTATION
To the Editor:
We read with interest the article
from Thistlethwaite and colleagues1
entitled ‘‘Airway stenoses after lung
transplantation: incidence, manage-
ment and outcome.’’
We agree that silicone stents are ex-
tremely useful to complete treatment
of posttransplantation airway stenosis
after mechanical/laser debridement;
they can effectively support the airway
during healing and prevent recurrence.
The use of this type of stent is particu-
larly indicated for type 1 and 2 stenosis
(according to the classification reported
by the authors), and they can be easily
fenestrated to allow ventilation to the
upper lobes when the bronchial stenosis
comes across them. However, we have
met some difficulties in placing these
stents when the stenosis is extremely
long and tortuous, encompassing also
the airway distal to the anastomosis for
a long segment or the peripheral airway
(type 3 and 4 stenosis). This is obvi-
ously a very small group of patients
(in the reported series there are only 3
[15%] patients), but this problem has
been certainly met by all the groups per-
forming lung transplantation, and the
difficulties in its treatment are evident.
When this type of complication occurs,
it usually requires several treatments
with unsatisfactory results, and perma-
nent stenting is usually indicated. In
this situation we have found extremely
useful the use of covered expandable
metallic stents (Ultraflex; Boston
Scientific, Galway, Ireland). They can
be easily deployed, completing airway
dilatation, and present a better ratio be-
tween the thickness of the wall of the
stent and the diameter of the stent itself,
allowing a better airflow, especially for
small diameters; thus clearance of se-
cretion is improved. Although they are
more expensive than silicone stents
and clearly more difficult to remove,
their use might be preferred in this sub-
set of patients. We have used them in 5
patients without major complications.
Could the authors provide more de-
tails about the group of patients with
type 3 and 4 stenosis?
Marco Anile, MD
Tiziano De Giacomo, MD
Federico Venuta, MD
University of Rome ‘‘Sapienza’’
Policlinico Umberto I
Rome, Italy
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We appreciate the interest that Drs
Anile and Ventura have in the manage-
ment of lung transplant recipients with
distal focal bronchial stenosis (type 3
disease) and diffuse distal stenosis
(type 4 disease). This is a complex
group of patients to manage, and their
airway issues can be challenging.1
As a high-volume center for bron-
chial stent placement (for causes other
than transplantation), we have been
uniformly disappointed with the use
of expandable metallic stents. Metallic
stents in the airway are expensive and
associated with fracture, overgrowth
of granulation tissue, and erosion
through the tracheobronchial wall.
Although the cost of a single metallic
stent is low in comparison with the
total expense of lung transplantation,
cost precludes having a large inventory
of these stents available. We currently
have an inventory of more than 100 Si-
lastic stents (Hood Laboratories, Pem-
broke, Mass, and Bryan Corporation,
Woburn, Mass). This inventory allows
us to find the right stent for almost any
airway, to tailor a specific stent to an
QUALITY IMPROVEMENT
PROGRAM DECREASES
MORTALITYAFTER CARDIAC
SURGERY
To the Editor:
We read with interest the article by
Stamou and colleagues,1 who showed
that a quality improvement program de-
creased mortality after cardiac surgery
in a large cohort, using a risk-adjusted
methodology. Most importantly, out-
comes improved mostly due to fewer
cardiac-related deaths. Moreover, there
was a lower relative decline in mortality
among patients with diabetes than
among those without diabetes, indicat-
ing the influence of patient individual
factors on outcomes. Finally, they con-
clude that future quality improvement
programs should focus on high-risk
patients, which they misclassified as
those with diabetes. It would be more
appropriate if the authors provide in-
formation about severity scores widely
available in the literature instead.
Quality improvement programs fol-
low institutional or regional/national
initiatives. Although the latter are im-
portant to monitor and foster improve-
ment of outcomes, the former are
fundamental to develop a sustained
and cost-effective system locally. Be-
cause processes of care vary widely
among cardiac surgery programs,
there are no ‘‘recipes’’ that can be uni-
versally applied, due to system-based
particularities. Core components of
the quality improvement program de-
scribed by Stamou and colleagues1
are important, but such programs
should be presented in a problem-
based approach. It would be interest-
ing to know the problems responsible
for the initial unfavorable outcomes.
That would potentially guide other
cardiac surgery centers in implement-
ing similar programs. Moreover, infor-
mation about the financial impact
(investment and savings) of those pro-
grams is crucial, particularly in times
of world economic crisis.
In Brazil, results of cardiac sur-
gery are not as good as in developed
countries.2 Reasons are multiple, but
certainly include different patient
profiles, social problems, limited re-
sources, and poorly developed hospital
operating systems and integrated patient
care. In our center, multimodal strate-
gies were added, aiming for team build-
ing and a more organized and integrated
hospital system. No substantial resource
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place/upsize them as needed.
We have several practical tips for stent-
ing of type 3 and 4 bronchial stenoses:
1. We have found that stenting of the
subsegmental airways does not
benefit the patient. Thus, we limit
our stenting to the bronchial and
segmental airways.
2. We calibrate the size of stent to be
placed based on the size of the rigid
bronchoscope that we are able to in-
sert in the portion of bronchus af-
fected. For example, if we are able
to cannulate the affected bronchus
with a 10-mm rigid bronchoscope,
we would size the proximal portion
of the stent to 10 to 12 mm.
3. For difficult and long stenoses, we
often dilate the bronchus/segment
and insert as large a stent as possi-
ble. In 2 to 3 months, we remove
the stent and replace it with a larger
diameter stent. This can be done
sequentially to maximally dilate
the affected area.
4. For distal left-sided problems, we
routinely place the stent over the bi-
furcation of the upper and lower
lobes and cut a small circular seg-
ment out of the stent using a 6-
mm dermal punch (Acuderm, Fort
Lauderdale, FL). This stent con-
touring maintains the integrity of
the stent while allowing for ventila-
tion of the upper lobe, which would
otherwise be obstructed.
5. For distal right-sided problems, we
use step-down stents of various
configurations (Hood Silastic 2-
Step Stents with Posts and Mesh:
Hood Laboratories). A step-down
stent is one in which the proximal
diameter is larger than the distal di-
ameter, with tapering of the stent
diameter in between. Step-down
stents allow coverage down to the
level of the superior segment of
the lower lobe and right middle
lobe, while maintaining patency
and coverage of the anastomosis
and proximal mainstem bronchus.
We usually cut a 6-mm dermalThe Journapunch hole in the stent for the right
upper lobe to allow ventilation to
this lobe. The right upper lobe ori-
fice is often variable in its position,
so we have not found stents with
premade orifices effective for use.
6. While inserting Silastic stents, we
have found that it is important to
place the hole for a lobar orifice
corresponding to the print on the
metallic applicator (Dumon-Harrell
applicator: Bryan Corporation).
This configuration allows for easy
rotation of the stent (clockwise for
right bronchial stents, counterclock-
wise for left bronchial stents) into
the appropriate position as it is
deployed. After stent deployment,
we then often put a flexible bron-
choscope through the rigid bron-
choscope into the stent while using
rigid forceps to manipulate the
hole into its most optimal position.
Our experience has been that bron-
choscopic surveillance and sequential
‘‘up-size’’ stenting for distal long-seg-
ment stenoses is an effective way to
permanently increase luminal diame-
ter over a long length of airway.
Patricia A. Thistlethwaite, MD, PhDa
James Harrell, MDb
aDivision of Cardiothoracic Surgery
bDivision of Pulmonary and Critical
Care Medicine
University of California, San Diego
San Diego, Calif
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